Home Free Dental Care States Medicaid Submit Procedure List Foreign Research Contact
 

Dental Research Programs in Tucson AZ


Apnea Positive Pressure Long-Term Efficacy Study

This study is currently recruiting patients

Verified by National Heart, Lung, and Blood Institute (NHLBI) April 2006

Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier: NCT00051363


Purpose

The purpose of this study is to determine the effectiveness of nasal continuous positive airway pressure (CPAP) therapy for the treatment of obstructive sleep apnea syndrome (OSAS).


Condition Intervention Phase
Lung Diseases
Sleep Apnea Syndromes
Sleep
Device: Positive Pressure Respiration Phase III

Study Type: Interventional
Study Design: Treatment, Randomized

Official Title: APPLES: Apnea Positive Pressure Long-Term Efficacy Study

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):
Primary Outcomes: Effect of CPAP on neurocognitive function (measured at Month 6)
Secondary Outcomes: Attention and psychomotor (A/P) function; Learning and memory (L/M) function; Executive and frontal-lobe (E/F) function; Sleepiness/Alertness; Mood; Quality of Life (all measured at Month 6)
Expected Total Enrollment:  1100

Study start: September 2002

BACKGROUND:

Nasal CPAP therapy is in widespread use as the primary treatment for OSAS, a sleep-related breathing disorder affecting more than 15 million Americans. The therapeutic effectiveness of CPAP in providing significant, stable, and long-term neurocognitive or other functional benefits to patients with OSAS has not been systematically investigated.

DESIGN NARRATIVE:

The study is a randomized, blinded, sham-controlled, multi-center trial of CPAP therapy. The principal aims of the study are: 1) to assess the long-term effectiveness of CPAP therapy on neurocognitive function, mood, sleepiness, and quality of life by administering tests of these indices to subjects randomly assigned to active or sham CPAP; 2) to identify specific neurocognitive deficits associated with OSAS in a large, heterogeneous subject population; 3) to determine which deficits in neurocognitive function in OSAS subjects are reversible and most sensitive to the effects of CPAP; 4) to develop a composite multivariate outcome measure from the results of this study that can be used to assess the clinical effectiveness of CPAP in improving neurocognitive function, mood, sleepiness, and quality of life; and 5) to use functional magnetic resonance imaging to compare cortical activation before and after CPAP therapy, and to assess whether this change is associated with improvement in specific neurocognitive task performance. The primary endpoint of the study is the effect of six months of CPAP treatment on neurocognitive function. A total of 1100 subjects (550 per treatment group) will be enrolled from the patient populations at five sites (Stanford University; University of Arizona; Harvard Medical School; St. Luke's Hospital, Missouri; St. Mary's Hospital, Washington).

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

  • Male or female adults age 18 years or older with a diagnosis of OSAS using clinical criteria defined by the study protocol
  • Study participation may require seven or more laboratory visits over six months

Exclusion Criteria:

  • Prior treatment for OSAS with continuous positive airway pressure or surgery
  • Potential sleep apnea complications that may affect the health or safety of the participant, including low blood oxygen, recent near-miss or prior automobile accident due to sleepiness, congestive heart failure, history of angina, coronary artery disease, myocardial infarction or stroke, cardiac rhythm disturbance, and chronic neurological disorders affecting neurocognitive abilities or daily function
  • The use of hypnotics, anxiolytics, sedating antidepressants, anticonvulsants, sedating antihistamines, stimulants or other medications likely to affect neurocognitive function and/or alertness
  • Respiratory disease requiring medications (unless on stable medications for 2 months)
  • Cancer, unless in remission for greater than one year and not taking exclusionary medications
  • Self-reported renal failure
  • Pregnancy anytime during a subject's participation
  • Psychiatric illness, as defined by a DSM-IV diagnosis, except for depression or mild anxiety
  • Narcolepsy, idiopathic hypersomnolence, DSM-IV chronic insomnia, restless legs syndrome, or rapid eye movement (REM) behavior disorder
  • Current use of diurnal or nocturnal supplemental oxygen
  • Significant vision, hearing, or coordination problems
  • Difficulty understanding or speaking English
  • Currently working night or rotating shifts
  • Consumption of >10 caffeinated beverages per day (approximately 1,000 mg per day)
  • Smokers whose habit interferes with the overnight polysomnogram or with the battery of testing during the day
  • Consumption of >2 alcoholic beverages per day
  • Any illicit drug usage or marijuana usage >1/wk
  • Any individual in the household currently on CPAP or on CPAP in the past
  • A score of 26 or less on the Mini Mental State Examination (MMSE)

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00051363

Deborah Nichols       debeen@moscow.com
Clete Kushida, MD       clete@stanford.edu

Arizona
University of Arizona AHSC, Tucson,  Arizona,  85724,  United States; Recruiting
Chuck Wynstra  520-626-5001    chuck@arc.arizona.edu 
Stuart Quan,  Principal Investigator

California
Stanford University School of Medicine, Palo Alto,  California,  94305,  United States; Recruiting
Eileen Leary  650-724-9639    eleary@stanford.edu 
Christian Guilleminault,  Principal Investigator

Massachusetts
Brigham & Women's Hospital, Boston,  Massachusetts,  02459,  United States; Recruiting
Denise Clarke  617-527-2227  Ext. 146    dclarke@rics.bwh.harvard.edu 
David White,  Principal Investigator
Daniel Gottlieb,  Principal Investigator

Missouri
St. Luke's Hospital, Chesterfield,  Missouri,  63017,  United States; Recruiting
Paula Schweitzer  314-205-6325    schwpk@stlo.smhs.com 
James Walsh,  Principal Investigator

Washington
St. Mary Medical Center, Walla Walla,  Washington,  99362,  United States; Recruiting
Kevin Hurburt  509-522-5845    hurlke@smmc.com 
Richard Simon,  Principal Investigator

Study chairs or principal investigators

William Dement,  Principal Investigator,  Stanford University   

More Information

Study ID Numbers:  150; U01 HL068060
Last Updated:  May 16, 2006
Record first received:  January 9, 2003
ClinicalTrials.gov Identifier:  NCT00051363
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2006-10-18





[Home]   [State Directory]   [Free Treatment]   [Foreign Directory]   [Contact]   [Submit Research]  
Dentistry Research Programs Directory
Tucson Arizona AZ
A Featured part of
Dental Research Programs featured in Dental Health Library
Oral Health Research Issues in Dentistry
All rights reserved - 1999-2014
Powered by DentMedHost
webmaster@dentalresearchprograms.com